ANISOTROPINE METHYLBROMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ANISOTROPINE METHYLBROMIDE (ANISOTROPINE METHYLBROMIDE).
Anisotropine methylbromide is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors (M1, M2, M3), thereby inhibiting parasympathetic nerve impulses. This leads to relaxation of smooth muscle in the gastrointestinal tract, decreased gastric acid secretion, and reduced motility.
| Metabolism | Primarily excreted unchanged in urine; minimal hepatic metabolism via ester hydrolysis to inactive metabolites. |
| Excretion | Primarily renal (approx. 70-80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for 20-30%, mainly as metabolites. |
| Half-life | Terminal elimination half-life is approximately 1.5-2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 8-10 hours). |
| Protein binding | Approximately 15-25% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Approximately 2.0-3.5 L/kg, indicating extensive tissue distribution beyond extracellular fluid. |
| Bioavailability | Oral: 10-25% due to extensive first-pass metabolism; bioavailability is highly variable and dose-dependent. |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-15 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | Oral: 6-8 hours; Intravenous/Intramuscular: 4-6 hours. Duration is dose-dependent and may be extended in hepatic or renal impairment. |
Adult: 1-2 mg intramuscularly or subcutaneously every 4-6 hours as needed. Maximum: 8 mg/day.
| Dosage form | TABLET |
| Renal impairment | GFR ≥ 30 mL/min: No adjustment. GFR < 30 mL/min: Avoid use due to risk of prolonged anticholinergic effects. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B/C: Use with caution; reduce dose by 50% due to decreased metabolism. |
| Pediatric use | Children ≥ 6 months: 0.05-0.1 mg/kg intramuscularly or subcutaneously every 4-6 hours; maximum single dose 0.4 mg. |
| Geriatric use | Start with lowest effective dose (1 mg) due to increased sensitivity to anticholinergic effects; avoid in patients with cognitive impairment or delirium risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ANISOTROPINE METHYLBROMIDE (ANISOTROPINE METHYLBROMIDE).
| Breastfeeding | No human data on excretion into breast milk. M/P ratio unknown. Consider potential for anticholinergic effects in infant; monitor for constipation, dry mouth, or tachycardia. |
| Teratogenic Risk | Limited human data; animal studies not available. Theoretical risk of anticholinergic effects on fetal development. First trimester: avoid unless essential. Second and third trimesters: use with caution, may cause fetal tachycardia or decreased GI motility. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to anisotropine methylbromide or any component; narrow-angle glaucoma; obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy); obstructive gastrointestinal tract disease (e.g., pyloroduodenal stenosis, intestinal atony); severe ulcerative colitis; myasthenia gravis; hiatal hernia associated with reflux esophagitis; unstable cardiovascular status in acute hemorrhage.
| Precautions | Risk of heat prostration in high environmental temperature due to decreased sweating; caution in patients with glaucoma, prostatic hypertrophy, and urinary retention; may cause drowsiness or blurred vision; avoid in patients with gastroesophageal reflux disease (GERD) due to delayed gastric emptying; use caution in elderly patients due to increased sensitivity to anticholinergic effects. |
| Food/Dietary | No significant food interactions. However, high-fiber foods may reduce absorption; take on an empty stomach for consistent effect. Alcohol may enhance CNS depression and anticholinergic effects. |
Loading safety data…
| Monitor maternal heart rate, urinary retention, and bowel function. Fetal monitoring for heart rate and movement if used long-term. |
| Fertility Effects | Anticholinergic drugs may impair fertility due to effects on cervical mucus and fallopian tube motility. Reversible upon discontinuation. |
| Clinical Pearls | Anisotropine methylbromide is a quaternary ammonium anticholinergic with poor CNS penetration, minimizing central side effects. It is used primarily for gastrointestinal disorders like peptic ulcer and irritable bowel syndrome. Monitor for anticholinergic effects (dry mouth, blurred vision, urinary retention) especially in elderly. Contraindicated in glaucoma, myasthenia gravis, obstructive uropathy, and gastrointestinal obstruction. |
| Patient Advice | Take exactly as prescribed, usually before meals and at bedtime. · Avoid alcohol and excessive heat, as this may increase risk of heat stroke due to decreased sweating. · Do not drive or operate machinery if you experience blurred vision or dizziness. · Report immediately if you experience eye pain, difficulty urinating, or severe constipation. · Use caution in hot weather as this medication can reduce sweating and increase risk of heat exhaustion. · Do not take with other anticholinergic medications without consulting your doctor. |